Day: April 5, 2021

The post-grant review period for U.S. Patent 10,696,730 covering the composition of matter of ALX148 ended on March 30, 2021.This patent provides coverage of ALX148 until at least 2036, not including term adjustments or extensions.BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announces that the post-grant review period for granted U.S. Patent No. 10,696,730 ended on March 30, 2021. This patent covers the lead product candidate ALX148, a next generation CD47-blocking therapeutic that combines a high-affinity signal regulatory protein-alpha (“SIRP“) CD47-binding domain fused with an inactivated, proprietary Fc domain. The U.S. patent is not expected to expire...

XBAW WiFi 6E Coexistence Filter Solution Has Been Evaluated and Approved for Multiple Chipsets New Market Leading SoC Customer Will Create a One-to-Many Sales Opportunity for XBAW WiFi 6E Coexistence SolutionCharlotte, N.C., April 05, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today its leading XBAW® WiFi 6E coexistence filter solutions have been approved for use in multiple reference designs by a second tier-1 system-on-chip (SoC) maker. The 5.5 GHz filter module covers the UNII 1-3 spectrum of the WiFi 6E standard, while the 6.5 GHz filter module covers the UNII 5-8 spectrum. The SoC maker has multiple MU-MIMO multiple chipset...

VANCOUVER, British Columbia, April 05, 2021 (GLOBE NEWSWIRE) — ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (OTC:PTNYF) (CSE:PKG) (FSE:PT0) is pleased to announce the signing of an agreement to provide delivery services with Bayshore Specialty Rx (specialty pharmacy, infusion and pharmaceutical patient support services). They are a subsidiary of Bayshore Health which is one of Canada’s leading providers of home and community healthcare services. With over 100 locations across the country, including 65 home care offices, 13 pharmacies and 90+ clinics, Bayshore has more than 13,500 staff members and provides care to over 350,000 clients. ParcelPal will be providing same day and next day prescription delivery to different facilities in the Vancouver, British Columbia area to start, with other cities to follow. CEO Rich...

THE WOODLANDS, Texas, April 05, 2021 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today that it will release its first quarter 2021 operating results on Wednesday, April 28, 2021, after the market closes. The Company has scheduled a conference call for Thursday, April 29, 2021, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss the results. The call will be available by live webcast on ChampionX’s website at https://investors.championx.com or by dialing in as follows:          US and Canada:     1-888-424-8151  International:     1-847-585-4422  Reference:     ChampionX conference call number 7046887Please register for the webcast or dial into the call approximately 15 minutes prior to the scheduled start time. A replay of the conference call will be available...

SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered into an agreement with East West Bank (“EWB”) in which EWB will provide a $7.5 million working capital line of credit. The line of credit is secured by Journey Medical’s receivables and cash. Interest on the line is the greater of 4.25% or the Prime Rate plus 1%. The agreement expires in 36 months. Journey Medical intends to use the proceeds for general corporate purposes, including the advancement of the Company’s portfolio. Claude Maraoui, President and Chief Executive Officer of Journey Medical, stated, “We are pleased to work with EWB to support our operating needs and future growth ambitions. With access...

– Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options – Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 – Global Phase 1/2 trial – GALax-C – PBKR03 planned to initiate in first half of 2021 PHILADELPHIA, April 05, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). The designation was based on a positive opinion from the European Medicines...

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen (BP1001), a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia (AML) patients. The safety run-in of Stage 2 of the Phase 2 clinical trial was comprised of six evaluable patients who were treated with the triple combination of prexigebersen, decitabine and venetoclax. “We are particularly pleased with the clean side effect profile and lack of toxicity...

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma Development of First-Generation ETB MT-3724 Has Been Discontinued, Company to Focus on Development of Next-Generation ETB Product Candidates Including Clinical Stage MT-5111, TAK-169 and MT-6402 AUSTIN, Texas, April 05, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that, following discussion with its co-development partner Takeda, MTEM will assume full rights to TAK-169 including taking control of clinical development from Takeda. In addition, MTEM announced the decision to...

~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130in Europe in the second half of 2021 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 05, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year. “This is an important milestone in our ongoing clinical development of AMT-130,” stated David Cooper, M.D., vice president, clinical...